摘要
背景与目的:miR-181b在多种肿瘤中表达异常,并参与调节多种抗肿瘤药物的敏感性。研究发现miR-181b在胶质瘤中具有起类似抑癌基因的作用,可作为胶质瘤的独立预后指标。本研究旨在进一步探讨恶性胶质瘤中miR-181b表达的临床意义及miR-181b对替莫唑胺化疗敏感性的影响。方法:收集不同病理级别胶质瘤标本,以荧光定量PCR法检测其中miR-181b的表达,分析其与胶质瘤病理分级及患者预后的关系;利用CCK-8细胞毒性实验检测患者恶性胶质瘤细胞对替莫唑胺的敏感性,并分析其与miR-181b表达的关系。结果:miR-181b在胶质瘤组织中的表达显著低于正常脑组织(P<0.05),miR-181b的表达水平分别为:正常脑组织3.69±0.477,WHOⅠ级2.56±0.354,WHOⅡ级0.81±0.222,WHOⅢ级0.42±0.130,WHOⅣ级0.21±0.067。miR-181b表达低的患者中位生存期为370±37天,而miR-181b表达高的患者中位生存期为493±60天(P<0.05)。在高级别胶质瘤中,miR-181b的表达与替莫唑胺的敏感性呈正相关(r=-0.576,P<0.001)。结论:miR-181b在胶质瘤中的表达与胶质瘤的病理级别呈负相关,而与脑胶质瘤患者预后呈正相关,与高级别胶质瘤对替莫唑胺的敏感性呈正相关。
BACKGROUND ＆ OBJECTIVE： It has been reported that miR-181b was downregulated in several cancer types and the aberrant expression was associated with drug resistance, miR-181h is known to function as a turnout suppressor gene and serves as a prognostic marker in human glioma. The purpose of this study is to evaluate miR-181b expression in gliomas and its clinical significance, as well as to temozolomide（TMZ） sensitivity. METHODS： The expression level of miR-181b was measured by qRT-PCR for frozen h to determine growth inhibiting effects of temozolomide uman glioma specimens. CCK-8 was used （TMZ） on the primary glioma samples. RESULTS： miR-181b expression in normal brain tissu±e and glioma samples of WHO grade I, II, IIIand IV was 3.69 ± 0.477, 2.56 ± 0.354, 0.81 ± 0.222, 0.42 ± 0.130 and 0.21 ± 0.067, respectively. There were significant differences between normal brain and each glioma groups （P 〈 0.05）. Median survival time of patientswith low level of miR-181b was 370 ± 37 days, while with high level of miR-181b was 493 ± 60 days. TMZ Sensitivity was measured for 48 high grade gliomas （WHO m/IV） , it showed significant positive association with miR-181b expression （r=-0.576, P 〈 0.001）. CONCLUSIONS： miR-181b expression is generally lower in human gliomas, and is negatively associated to tumor grade but positively to prognosis of the patients. The miR-181b expression level is also positively correlated to temozolomide sensitivity in high grade gliomas.
出处
《中国神经肿瘤杂志》
2013年第1期1-7,共7页
Chinese Journal of Neuro-Oncology
基金
国家高技术研究发展计划(863计划)重大项目"重大疾病分子分型与个体化诊疗技术"
